Spike Protein Trimer

Description: The SARS-CoV-2 IgG detection kit is designed for qualitative detection of human IgG antibodies in serum collected from individuals suspected of prior infection with the virus that causes COVID-19. This fast and simple ELISA uses the trimeric form of the SARS-CoV-2 Spike protein (BPS Bioscience #100728) to identify IgG antibodies that indicate a previous infection with SARS-CoV-2. The Spike protein is expressed on the viral membrane as a trimer, which means this kit measures IgG antibodies in a more physiologically relevant context than many other commercially available ELISA kits. 

Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein contains three mutations: K417T, E484K and N501Y that have been found in emerging SARS-CoV-2 Variants of Concern and may lead to higher transmissibility and infectivity. This mutant Spike Trimer will be useful for structure-function studies, testing of neutralizing antibodies, or antibody and drug screening.  The construct also contains a C-terminal His-tag. Note that the expected MW of the S1+S2 monomer is 136kDa but migrates at a higher MW in SDS-PAGE due to glycosylation. The recombinant protein is ?90% pure following affinity purification.

Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein contains three mutations: K417T, E484K and N501Y that have been found in emerging SARS-CoV-2 Variants of Concern and may lead to higher transmissibility and infectivity. This mutant Spike Trimer will be useful for structure-function studies, testing of neutralizing antibodies, or antibody and drug screening.  _x000D_The construct also contains a C-terminal His-tag. Note that the expected MW of the S1+S2 monomer is 136kDa but migrates at a higher MW in SDS-PAGE due to glycosylation. The recombinant protein is ?90% pure following affinity purification.

Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein corresponds to SARS-CoV2 Variant P.1 originally discovered in Brazil and contains 11 mutations in addition to 682RRAR685>A, K986P and V987P, as listed below. The construct also contains a C-terminal His-tag. Note that the expected MW of the S1+S2 monomer is 136kDa but migrates at a higher MW in SDS-PAGE due to glycosylation. The recombinant protein is ≥90% pure following high affinity Ni-NTA purification.

Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein corresponds to SARS-CoV2 Variant P.1 originally discovered in Brazil and contains 11 mutations in addition to 682RRAR685>A, K986P and V987P, as listed below. The construct also contains a C-terminal His-tag. Note that the expected MW of the S1+S2 monomer is 136kDa but migrates at a higher MW in SDS-PAGE due to glycosylation. The recombinant protein is ≥90% pure following high affinity Ni-NTA purification.

Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein corresponds to SARS-CoV-2 Variant B.1.429, also known as variant Epsilon, originally identified in California (USA), and contains mutations W152C, L452R, D614G in addition to 682RRAR685>A and K986P, V987P. The construct also contains a C-terminal His-tag (6His). The recombinant protein was affinity purified.

Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein corresponds to SARS-CoV-2 Variant B.1.351, also known as variant Beta originally discovered in South Africa, and contains the nine known mutations listed below, in addition to deletion 242-244. It also contains mutations 682RRAR685>A, K986P and V987P. The construct has a C-terminal His-tag (6xHis). Note that the expected MW of the S1+S2 monomer is 137kDa but migrates at a higher MW in SDS-PAGE due to glycosylation. The recombinant protein was affinity purified.

*Deletion 242-244 is known as 241-243 in some databases and on the CDC website. This is the same deletion. As stated by Tegally et al., Nature 2021: "We also observe a deletion of three amino acids at positions 242 to 244, which was seen in samples extracted and generated in different laboratories across the NGS-SA. This region is difficult to align; the deletion could potentially also be located at positions 241 to 243, but the resulting sequence would be exactly the same. "

Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein corresponds to SARS-CoV-2 Variant B.1.617 originally discovered in India, and contains mutations L452R, E484Q, D614G and P681R. The construct also contains mutations 682RRAR685>A, K986P and V987P, and a T4 trimerization domain followed by a His-tag (6xHis) in C-terminal. The recombinant protein was affinity purified._x000D_ 

Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein corresponds to SARS-CoV-2 Variant B.1.618, originally identified in India, and contains deletion 145/146YH as well as mutations E484K and D614G.  The construct also contains mutations 682RRAR685>A, K986P and V987P, and a T4 trimerization domain followed by a His-tag (6xHis) in C-terminal. The recombinant protein was affinity purified.

Description: Severe acute respiratory syndrome (SARS) is a viral respiratory illness caused by a corona virus called SARS-CoV-1. It was first reported in February 2013 in Asia and the epidemic affected ~ 26 countries and resulted in more than 8000 deaths. Like SARS-CoV-2, SARS-CoV-1 Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-1 and ACE2 may offer some protection against the viral infection. The SARS-CoV-1 Spike Trimer (S1+S2):ACE2 Inhibitor Screening Assay Kit includes the SARS-CoV-1 Spike protein in its native trimeric conformation to provide a more physiologically relevant screen for inhibitors as well as a compatible platform to investigate the specificity of SARS-CoV-2:ACE2 inhibitors._x000D_
The key to this kit is that the SARS-CoV-1 Spike Trimer (S1+S2) protein provides a more biologically relevant model than monomeric Spike RBD protein for the investigation of SARS-CoV-1/host cell interaction. Only a few simple steps on a microtiter plate are required for the assay. First, SARS-CoV-1 Spike Trimer (S1+S2) is coated on a 96-well plate. Next, Biotin-ACE2 is incubated with SARS-CoV-1 Spike Trimer (S1+S2) on the plate. Finally, the plate is treated with Streptavidin-HRP followed by addition of a colorimetric HRP substrate to produce color, which then can be quenched and measured using a UV/Vis microplate reader.

Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The Spike glycoprotein is expressed on the surface of the virus as a trimer. Each Spike protein consists of two subunits, S1 and S2, and the S1 subunit has a receptor binding domain (RBD) which recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer some protection against the viral infection. The SARS-CoV-2 Spike Trimer (S1+S2) :ACE2 Inhibitor Screening Assay Kit includes the Spike protein in its native trimeric conformation to provide a more physiologically relevant screen for inhibitors of the Spike S1:ACE2 interaction._x000D_The SARS-CoV-2 Spike Trimer (S1+S2) :ACE2 Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of this interaction. The key to this kit is that the SARS-CoV-2 Spike Trimer (S1+S2) protein provides a more biologically relevant model than monomeric Spike RBD protein for the investigation of SARS-CoV-2/host cell interaction. Only a few simple steps on a microtiter plate are required for the assay. First, SARS-CoV-2 Spike Trimer (S1+S2) is coated on a 96-well plate. Next, Biotin-ACE2 is incubated with SARS-CoV-2 Spike Trimer (S1+S2) on the plate. Finally, the plate is treated with Streptavidin-HRP followed by addition of a colorimetric HRP substrate to produce color, which then can be quenched and measured using a UV/Vis microplate reader.

Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein corresponds to SARS-CoV-2 Variant B.1.617.1 also known as variant Kappa originally identified in India, and contains mutations G142D, E154K, L452R, E484Q, D614G, P681R and Q1071H. The construct also contains mutations 682RRAR685>A, K986P and V987P, and a T4 trimerization domain followed by a His-tag (6xHis) in C-terminal. The recombinant protein was affinity purified.

Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein corresponds to SARS-CoV-2 Variant B.1.617.1 also known as variant Kappa originally identified in India, and contains mutations G142D, E154K, L452R, E484Q, D614G, P681R and Q1071H. The construct also contains mutations 682RRAR685>A, K986P and V987P, and a T4 trimerization domain followed by a His-tag (6xHis) in C-terminal. The recombinant protein was affinity purified.

Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein corresponds to SARS-CoV-2 Variant B.1.617.2, also known as variant Delta, originally discovered in India. It contains the eight Delta variant mutations indicated below in addition to deletion 156/157. The construct also contains mutations 682RRAR685>A, K986P and V987P, and a T4 trimerization domain followed by a His-tag (6xHis) in C-terminal. The recombinant protein was affinity purified. 

Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant XBB and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified.

Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant XBB and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified.

Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein corresponds to SARS-CoV-2 Variant B.1.617.2.1 also known as variant Delta Plus originally identified in India, and contains mutations T19R, G142D, R158G, K417N, L452R, T478K, D614G, P681R and D950N as well as deletion E156-F157.  The construct also contains mutations 682RRAR685>A, K986P and V987P, and a T4 trimerization domain followed by a His-tag (6xHis) in C-terminal. The recombinant protein was affinity purified.